Paul Mahon Sells 11,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $484.67, for a total value of $5,331,370.00. Following the transaction, the executive vice president owned 36,781 shares of the company’s stock, valued at $17,826,647.27. This represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

United Therapeutics Stock Performance

UTHR stock opened at $493.99 on Friday. The stock’s 50 day moving average price is $457.81 and its 200 day moving average price is $374.43. The firm has a market cap of $21.27 billion, a P/E ratio of 18.72, a PEG ratio of 4.90 and a beta of 0.86. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $496.73.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.39 earnings per share. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Clearstead Advisors LLC increased its holdings in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of United Therapeutics by 2.6% in the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the period. Archer Investment Corp lifted its stake in shares of United Therapeutics by 9.5% in the 3rd quarter. Archer Investment Corp now owns 356 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 31 shares in the last quarter. F m Investments LLC grew its holdings in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares during the period. Finally, HB Wealth Management LLC increased its position in United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Bank of America upped their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research note on Tuesday, September 2nd. Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 10th. UBS Group boosted their price target on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Royal Bank Of Canada raised their price objective on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.